News

BIO-CAT Partners with Kerry for Global Distribution of OPTI-BIOME MB40 Probiotic

BIO-CAT, Inc. has formed a global partnership with Kerry, the Taste & Nutrition company and their BIO-CAT Microbials, LLC probiotic products division. Effective June 2021, Kerry will lead the sales, marketing, and distribution of BIO-CAT’s proprietary probiotic strain, OPTI-BIOME MB40®.

OPTI-BIOME MB40® (Bacillus subtilis ATCC122264) is a non-GMO, highly-stable probiotic strain that the company says is an ideal ingredient for a wide array of dietary supplements and other related uses. A 2019 peer-reviewed study demonstrated promising results for the probiotic strain to support gastrointestinal health.

Kerry has extensive success marketing probiotics — the Ireland-based company has placed its GanedenBC30® (Bacillus coagulans GBI-30, 6086) probiotic in well over 1,000 food and beverage products around the world. BIO-CAT CEO Chris Schuler said he envisions similar success with MB40® in the dietary supplement space.

“Given the impressive performance of the MB40® strain and its potential to have a significant impact on the dietary supplement, functional food and beverage, and companion animal industries, we have decided to work with a partner who will help scale MB40® globally,” Schuler said. “Kerry’s expertise, commitment to develop a leading probiotic platform, access to global resources, and plans to further scientifically support MB40® make them an ideal partner.”

As part of the agreement, Kerry will apply its brand development capabilities to refresh the MB40® brand over the course of the coming months. Once fully developed, the new brand name will be supported by Kerry’s global marketing and commercial infrastructure — the company currently boasts a network of nearly 150 locations across 31 countries. According to John Quilter, VP & General Manager of Kerry’s ProActive Health business, “We are delighted to partner with Bio-Cat to further develop and market this unique and highly-stable Bacillus strain, which will complement our growing portfolio of science-backed branded ingredients in our ProActive Health portfolio.”

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …